arrow_back Trending Legislation
Share share

Ban on mifepristone for abortion and new federal lawsuits against manufacturers

This bill withdraws federal approval for the drug mifepristone when used for abortion. It also establishes a new right for individuals to sue manufacturers for physical or mental harm caused by the drug.
Key points
Withdrawal of FDA approval for mifepristone for pregnancy termination within 14 days of enactment.
Ban on the interstate sale and distribution of the drug for abortion purposes.
New federal right to sue manufacturers for physical, psychological, or emotional injuries.
Victims can seek compensatory damages, punitive damages, and recovery of legal fees.
The drug will be considered misbranded if labeled for use in terminating pregnancies.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Introduced
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Safeguarding Women from Chemical Abortion Act
Print number: HR 7902
Sponsor: Rep. Harshbarger, Diana [R-TN-1]
Process start date: 2026-03-12
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Ban on mifepristone for abortion and new federal lawsuits against manufacturers

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 7902.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2026-03-12.

What are the main provisions?

Key points include:

  • Withdrawal of FDA approval for mifepristone for pregnancy termination within 14 days of enactment.
  • Ban on the interstate sale and distribution of the drug for abortion purposes.
  • New federal right to sue manufacturers for physical, psychological, or emotional injuries.
  • Victims can seek compensatory damages, punitive damages, and recovery of legal fees.
  • The drug will be considered misbranded if labeled for use in terminating pregnancies.

What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Harshbarger, Diana [R-TN-1].

What is the latest detailed status?

The latest detailed status is: Introduced in House

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-04-22.

Analysis and Potential Impact of HR 7902

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health Courts and Law